PTX-022 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 278 | 巨大リンパ管奇形（頚部顔面病変） | 1 |
278. 巨大リンパ管奇形（頚部顔面病変）
臨床試験数 : 22 / 薬物数 : 27 - (DrugBank : 7) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 63
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05050149 (ClinicalTrials.gov) | September 15, 2021 | 8/9/2021 | Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations | A Multicenter, Phase 2, Open-Label Study Evaluating The Safety And Efficacy of Sirolimus 3.9% Topical Gel (PTX-022) In The Treatment of Microcystic Lymphatic Malformations | Microcystic Lymphatic Malformation | Drug: PTX-022 | Palvella Therapeutics, Inc. | NULL | Recruiting | 13 Years | N/A | All | 15 | Phase 2 | United States |